Skip to content
CancerIndex

Loading the knowledge graph…

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL — knowledge graph · CancerIndex